MYNZ - Mainz Biomed N.V. Average Forecast Price

Mainz Biomed N.V. (MYNZ) specializes in cancer screening, offering a convenient at-home stool DNA test for detecting colorectal tumors as an alternative to invasive procedures. Business growth is constrained by prolonged regulatory reviews and R&D expenses, with the indicator standing at 14.00. This price trajectory for the securities on the GURU.Markets platform illustrates the asset's price action. Operational efficiency is supported by streamlined air transport of biomaterials to laboratories.

MYNZ (Mainz Biomed NV) Consensus Target history from 07/04/2022 to 03/11/2026

Analytical breakdowns for Mainz Biomed (MYNZ)

- market price and analyst price targets:

Stock Quotes mainzbiomed.com|MYNZ - Consensus Target

- market capitalization statistics:

Market Value Mainz Biomed N.V.|MYNZ - Total Company Value

- shareholders' equity book value data:

Equity per Share Mainz Biomed|MYNZ - Company Net Assets|Market Capitalization to Net Assets mainzbiomed.com|MYNZ - Company Total Assets

- issuer credit burden and liquidity indicators:

- net income and valuation multiples indicators:

MYNZ - Company Net Income|Expected Net Income Mainz Biomed N.V.|MYNZ - Price to Earnings Ratio|Future Price to Earnings Multiple mainzbiomed.com|MYNZ - PEG Multiple|EV/EBITDA Multiple Mainz Biomed N.V.|MYNZ - Profit before payment of interest, taxes and amortization|Earnings per share for the last 12 months Mainz Biomed|MYNZ - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth mainzbiomed.com|MYNZ - Earnings per share growth in current year|Net earnings per share growth forecast for next year Mainz Biomed N.V.

Fundamental company analysis:mainzbiomed.com (MYNZ)

This indicator reflects the weighted average fair value estimate of the shares, synthesizing professional analysts' forecasts regarding the company's future cash flows. By analyzing the dynamics of the market consensus target, an investor can identify a trend reversal, which for Mainz Biomed N.V. (MYNZ) directly correlates with the scaling efficiency of its partner laboratory network and the success of the global standardization of its diagnostic systems.

Competing companies